REM — Remedis SA Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -205.7% | ||
| Return on Equity | -174.88% | ||
| Operating Margin | -1478.6% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | PLNm | 0.49 | 0.74 | 0.18 | 0.05 | 0.04 | n/a | n/a | -43.13% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
REMEDIS SA is a Poland-based company principally engaged in the financial services provision. Its offer includes financial restructuring services, loan provision, creation of business analysis and restructuring programs, credit intermediation, factoring, as well as receivables purchase and debt collection. The Company's main clients are the Polish health care facilities and local government units. As of December 31, 2011 KLN Investments Sp. z o.o. held an 88% stake in REMEDIS SA. On April 2011, the Company merged with Inwest Consulting SA.
Directors
- Marcin Wyszogrodzki CEO
- P. Slawomir Kaminski SUB (49)
- Krzysztof Koszczynski SUB
- Kamil Krajewski SUB
- Wieslaw Markwitz SUB
- Przemyslaw Morysiak SUB
- Krzysztof Nowak SUB
- Michal Panczak SUB
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- December 28th, 2006
- Public Since
- November 19th, 2010
- No. of Employees
- 2
- Sector
- Banking Services
- Industry
- Financials
- Exchange
- Warsaw Stock Exchange
- Shares in Issue
- 63,300,102
- Address
- ul. Petera Mansfelda 4, POZNAN, 60-855
- Web
- http://remedis.eu/
- Phone
- +48 616657800
- Auditors
- FEHU GLOBAL AUDYT Sp. z o.o.
Upcoming Events for REM
Similar to REM
Akcept Finance SA
Warsaw Stock Exchange
Alior Bank SA
Warsaw Stock Exchange
Atlantis Se
Warsaw Stock Exchange
Bank Handlowy w Warszawie SA
Warsaw Stock Exchange
Bank Millennium SA
Warsaw Stock Exchange
FAQ
As of Today at 21:54 UTC, shares in Remedis SA are trading at PLN0.08. This share price information is delayed by 15 minutes.
Shares in Remedis SA last closed at PLN0.08 and the price had moved by +6.67% over the past 365 days. In terms of relative price strength the Remedis SA share price has outperformed the FTSE Global All Cap Index by +0.7% over the past year.
There is no consensus recommendation for this security.
Find out moreRemedis SA does not currently pay a dividend.
Remedis SA does not currently pay a dividend.
Remedis SA does not currently pay a dividend.
To buy shares in Remedis SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of PLN0.08, shares in Remedis SA had a market capitalisation of .
Here are the trading details for Remedis SA:
- Country of listing: Poland
- Exchange: WSE
- Ticker Symbol: REM
Based on an overall assessment of its quality, value and momentum Remedis SA is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Remedis SA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +65.21%.
As of the last closing price of PLN0.08, shares in Remedis SA were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Remedis SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at PLN0.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Remedis SA's management team is headed by:
- Marcin Wyszogrodzki - CEO
- P. Slawomir Kaminski - SUB
- Krzysztof Koszczynski - SUB
- Kamil Krajewski - SUB
- Wieslaw Markwitz - SUB
- Przemyslaw Morysiak - SUB
- Krzysztof Nowak - SUB
- Michal Panczak - SUB